Close Menu

IVF

Reproductive Medicine Associates of New Jersey is currently enrolling patients in a clinical validation trial of targeted next-generation sequencing-based preimplantation genetic testing to aid in the selection of embryos for transfer as part of in vitro fertilization.

This article was originally published on Jan. 29.
Microarrays are still a growing business for Illumina.

This article has been corrected to reflect that Illumina will seek Chinese FDA approval for a MiSeqDx-based NIPT assay, not a HiSeq2500-based assay, as previously reported.

Oxford Gene Technology this week launched a new microarray that can be used to screen embryos for chromosomal abnormalities prior to implantation during an in vitro fertilization cycle.

This story was originally posted on March 7

Illumina's acquisition of BlueGnome has provided a boost for its array business.

This story was originally posted on Oct. 24

Good Start Genetics has expanded the disorders it covers in its sequencing-based preconception carrier screening service to 23 after launching a more limited panel in April.

This article has been updated from a version posted Sept. 19 to include comments from Illumina officials.

Using arrays to screen embryos during an in vitro fertilization cycle can improve pregnancy rates, according to a new study.

Pages

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.